Jennifer L. Dickson

Jennifer L. Dickson

Auto-generated profile, based on publicly available information

Jennifer L. Dickson

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
STSophie Tisi
Sophie Tisi
JDJennifer L. Dickson
Jennifer L. Dickson
CHCarolyn Horst
Carolyn Horst
SQSamantha L. Quaife
Samantha L. Quaife
HHHelen Hall
Helen Hall
SJSam M. Janes
Sam M. Janes
Background: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort.Methods: 16 010 current or former smokers aged 55–77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCOm2012score ≥1.3% and/or meeting USPSTF 2013 criteria).Results: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1%versus53.2%; p<0.001), currently smoking (54.9%versus47.6%; p<0.001) and from an ethnic minority group (p<0.001). Undiagnosed COPD was associated with less forced expiratory volume in 1 s impairment (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 and 2: 85.3%versus68.4%; p<0.001) and lower symptom/exacerbation burden (GOLD A and B groups: 95.6%versus77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73–4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67–4.64; p<0.001).Conclusions: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer.

5 August 2020 in Thorax
Verified
Journal Article
Open access
PDF file
MRMamta Ruparel
Mamta Ruparel
SQSamantha L Quaife
Samantha L Quaife
JDJennifer L Dickson
Jennifer L Dickson
CHCarolyn Horst
Carolyn Horst
STSophie Tisi
Sophie Tisi
SJSam M Janes
Sam M Janes
The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based ‘real-world’ LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a ‘lung health check’. 768/996 (77.1%) in the present analysis underwent a low-dose CT scan. 92 (11.9%) and 33 (4.3%) participants had indeterminate pulmonary nodules requiring 3-month and 12-month surveillance, respectively; 36 lung cancers (4.7%) were diagnosed (median follow-up: 1044 days). 72.2% of lung cancers were stage I/II and 79.4% of non-small cell lung cancer had curative-intent treatment.

21 July 2022 in Thorax
Verified
Journal Article
Open access
PDF file
JDJennifer L Dickson
Jennifer L Dickson
HHHelen Hall
Helen Hall
CHCarolyn Horst
Carolyn Horst
STSophie Tisi
Sophie Tisi
PVPriyam Verghese
Priyam Verghese
SJSam M Janes
Sam M Janes
Eligibility for lung cancer screening (LCS) requires assessment of lung cancer risk, based on smoking history alongside demographic and medical factors. Reliance on individual face-to-face eligibility assessment risks inefficiency and costliness. The SUMMIT Study introduced a telephone-based lung cancer risk assessment to guide invitation to face-to-face LCS eligibility assessment, which significantly increased the proportion of face-to-face attendees eligible for LCS. However, levels of agreement between phone screener and in-person responses were lower in younger individuals and minority ethnic groups. Telephone-based risk assessment is an efficient way to optimise selection for LCS appointments but requires further iteration to ensure an equitable approach.

25 November 2022 in Thorax
Verified
Journal Article
Open access
PDF file
ACAndrew Creamer
Andrew Creamer
CHCarolyn Horst
Carolyn Horst
JDJennifer L Dickson
Jennifer L Dickson
STSophie Tisi
Sophie Tisi
HHHelen Hall
Helen Hall
SJSam M Janes
Sam M Janes
The optimal management of small but growing nodules remains unclear. The SUMMIT study nodule management algorithm uses a specific threshold volume of 200 mm3before referral of growing solid nodules to the multidisciplinary team for further investigation is advised, with growing nodules below this threshold kept under observation within the screening programme. Malignancy risk of growing solid nodules of size >200 mm3at initial 3-month interval scan was 58.3% at a per-nodule level, compared with 13.3% in growing nodules of size ≤200 mm3(relative risk 4.4, 95% CI 2.17 to 8.83). The positive predictive value of a combination of nodule growth (defined as percentage volume change of ≥25%), and size >200 mm3was 65.9% (29/44) at a cancer-per-nodule basis, or 60.5% (23/38) on a cancer-per-participant basis. False negative rate of the protocol was 1.9% (95% CI 0.33% to 9.94%). These findings support the use of a 200 mm3minimum volume threshold for referral as effective at reducing unnecessary multidisciplinary team referrals for small growing nodules, while maintaining early-stage lung cancer diagnosis.

2 June 2025 in Thorax
Verified
Journal Article
Open access
PDF file
ACAndrew Creamer
Andrew Creamer
CHCarolyn Horst
Carolyn Horst
RPRuth Prendecki
Ruth Prendecki
PVPriyam Verghese
Priyam Verghese
ABAmyn Bhamani
Amyn Bhamani
SJSam M Janes
Sam M Janes
Background: Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in solid nodules at baseline low-dose CT (LDCT) in a lung cancer screening (LCS) programme. Methods: This was an observational study using data from the SUMMIT Study, a prospective longitudinal study investigating LDCT for LCS. Participants were 55–77 years old and met either the United States Preventative Services Task Force (2013) criteria or had a PLCOm2012 risk of ≥1.3%. LDCTs were reported using computer-aided detection software (Veolity, MeVIS) with semiautomated volumetry. Cancer outcomes were reported for solid nodules reported at baseline CT, with participants represented by the single largest solid nodule where more than one was present. Malignancy risk was stratified by long-axis diameter and volume using predefined size thresholds taken from British Thoracic Society and European Position statement guidelines: a 5/6 mm long axis diameter or 80/100 mm3 volume ‘rule out’ thresholds for low-risk nodules and ≥300 mm3 or ≥8 mm diameter with or without Brock score ≥10% ‘Rule in’ thresholds for high-risk nodules. Pearson’s χ2 test was used to calculate statistical significance for nominal variables, McNemar’s test for comparison of sensitivity/specificity and DeLong’ test for comparison of areas under the receiver operating characteristic curve (AUROC). Optimal thresholds were determined with Youden’s J statistic. Net benefit calculations were undertaken to compare the existing thresholds with 95% CIs calculated by bootstrap sampling. Results: 11 355 participants were included. Crude risk of malignancy in solid nodules at baseline LDCT was 3.8% (228/5929). Risk of malignancy in solid nodules <6 mm long-axis diameter or <100 mm3 volume was equivalent to that in participants with no nodules at baseline LDCT (0.88% and 0.84% vs 0.77%, p=0.4600 and p=0.7932, respectively). A <80 mm3 volume and <5 mm diameter ‘rule out’ threshold achieved sensitivity 86.8% and 93.4%, specificity 65.4% and 24.64%, and negative predictive value (NPV) 99.2% and 98.9%, respectively. The <80 mm3 volume threshold encompassed 63.3% of participants with a baseline solid nodule compared with 24.0% by the <5 mm diameter threshold. For nodules ≥8 mm diameter, the addition of a risk score (Brock ≥10%) was associated with a significant net benefit when compared with using size threshold alone by net effect analysis (31.24; 95% CI 26.19 to 35.89). Conclusions: Solid nodules <100 mm3 or <6 mm diameter are not associated with increased risk of lung cancer compared with participants with no nodules at baseline LDCT. Volumetric rule-out thresholds achieve equivalent NPV to long-axis diameter thresholds while encompassing significantly more participants, reducing the number of interval scans required.

1 March 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CHC. Horst
C. Horst
JDJ. Dickson
J. Dickson
STS. Tisi
S. Tisi
HHH. Hall
H. Hall
PVP. Verghese
P. Verghese
SJS. Janes
S. Janes